How to assess start-up companies

Relevant soft factors to assess startup companies Investing in early stage companies is a risky business. In recent years, many venture capitalists have discovered painfully, the consequences of pursuing less than thorough risk assessments. Although it’s the negative experiences that tend to be heard first, it’s the success stories that make it all the more … Continue reading How to assess start-up companies

Read more

Life sciences Ontario, new long-term partner for Biotechgate

The new partner joins a group of over 30 partners worldwide, mainly Biotech Associations and Economic Development agencies. Biotechgate`s global partners include organisations in Canada (BIOTECanada), US, Switzerland, Netherlands, Germany, South Korea, Denmark, Sweden and the new member states in the European Union. With over 24’000 company profiles from around the world, Biotechgate (www.biotechgate.com ) … Continue reading Life sciences Ontario, new long-term partner for Biotechgate

Read more

How big Pharma companies structure their licensing deals – prepare for BIO 2012

Most companies dream about closing a licensing deal with big Pharma. But what do these deals really contain from a financial perspective and can any trends be found for potential big Pharma licensees in order to assist licensors in the deal making process?  To gain insight in these aspects, we have analyzed the financial deal … Continue reading How big Pharma companies structure their licensing deals – prepare for BIO 2012

Read more

Public Biotechs – Light at the end of the tunnel, although private Biotechs may have to wait a bit longer

Amsterdam March 2012: An overview of the state of the Biotech Industry was given by BIOs Industry Research & Analyst David Thomas at BIOEuropeSpring in Amsterdam. He made three main points: Public market have gained 25% in the last couple of month Private Biotechs still have a hard time to find investors Partnering and deal making … Continue reading Public Biotechs – Light at the end of the tunnel, although private Biotechs may have to wait a bit longer

Read more